271 related articles for article (PubMed ID: 28741260)
1. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.
Wellberg EA; Checkley LA; Giles ED; Johnson SJ; Oljira R; Wahdan-Alaswad R; Foright RM; Dooley G; Edgerton SM; Jindal S; Johnson GC; Richer JK; Kabos P; Thor AD; Schedin P; MacLean PS; Anderson SM
Horm Cancer; 2017 Dec; 8(5-6):269-285. PubMed ID: 28741260
[TBL] [Abstract][Full Text] [Related]
2. Cooperative Dynamics of AR and ER Activity in Breast Cancer.
D'Amato NC; Gordon MA; Babbs B; Spoelstra NS; Carson Butterfield KT; Torkko KC; Phan VT; Barton VN; Rogers TJ; Sartorius CA; Elias A; Gertz J; Jacobsen BM; Richer JK
Mol Cancer Res; 2016 Nov; 14(11):1054-1067. PubMed ID: 27565181
[TBL] [Abstract][Full Text] [Related]
3. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
[TBL] [Abstract][Full Text] [Related]
4. A surprising link between the energetics of ovariectomy-induced weight gain and mammary tumor progression in obese rats.
MacLean PS; Giles ED; Johnson GC; McDaniel SM; Fleming-Elder BK; Gilman KA; Andrianakos AG; Jackman MR; Shroyer KR; Schedin PJ
Obesity (Silver Spring); 2010 Apr; 18(4):696-703. PubMed ID: 19798068
[TBL] [Abstract][Full Text] [Related]
5. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer.
Giles ED; Wellberg EA; Astling DP; Anderson SM; Thor AD; Jindal S; Tan AC; Schedin PS; Maclean PS
Cancer Res; 2012 Dec; 72(24):6490-501. PubMed ID: 23222299
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
7. Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer.
Wellberg EA; Corleto KA; Checkley LA; Jindal S; Johnson G; Higgins JA; Obeid S; Anderson SM; Thor AD; Schedin PJ; MacLean PS; Giles ED
Breast Cancer Res; 2022 Jun; 24(1):42. PubMed ID: 35725493
[TBL] [Abstract][Full Text] [Related]
8. Postmenopausal obesity promotes tumor angiogenesis and breast cancer progression in mice.
Gu JW; Young E; Patterson SG; Makey KL; Wells J; Huang M; Tucker KB; Miele L
Cancer Biol Ther; 2011 May; 11(10):910-7. PubMed ID: 21451264
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.
Secreto G; Venturelli E; Meneghini E; Carcangiu ML; Paolini B; Agresti R; Pellitteri C; Berrino F; Gion M; Cogliati P; Saragò G; Micheli A
BMC Cancer; 2012 Dec; 12():599. PubMed ID: 23241075
[TBL] [Abstract][Full Text] [Related]
10. Expression of androgen receptor splice variants in clinical breast cancers.
Hickey TE; Irvine CM; Dvinge H; Tarulli GA; Hanson AR; Ryan NK; Pickering MA; Birrell SN; Hu DG; Mackenzie PI; Russell R; Caldas C; Raj GV; Dehm SM; Plymate SR; Bradley RK; Tilley WD; Selth LA
Oncotarget; 2015 Dec; 6(42):44728-44. PubMed ID: 26554309
[TBL] [Abstract][Full Text] [Related]
11. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
12. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
[TBL] [Abstract][Full Text] [Related]
13. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.
Rajarajan S; Korlimarla A; Alexander A; Anupama CE; Ramesh R; Srinath BS; Sridhar TS; Prabhu JS
Front Endocrinol (Lausanne); 2021; 12():679756. PubMed ID: 34234742
[TBL] [Abstract][Full Text] [Related]
14. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
Christenson JL; Butterfield KT; Spoelstra NS; Norris JD; Josan JS; Pollock JA; McDonnell DP; Katzenellenbogen BS; Katzenellenbogen JA; Richer JK
Horm Cancer; 2017 Apr; 8(2):69-77. PubMed ID: 28194662
[TBL] [Abstract][Full Text] [Related]
15. The role of androgens in mammary carcinogenesis.
Wong YC; Xie B
Ital J Anat Embryol; 2001; 106(2 Suppl 1):111-25. PubMed ID: 11729946
[TBL] [Abstract][Full Text] [Related]
16. Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: probable mediation by steroid receptors.
Liao DZ; Pantazis CG; Hou X; Li SA
Carcinogenesis; 1998 Dec; 19(12):2173-80. PubMed ID: 9886575
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.
Caiazza F; Murray A; Madden SF; Synnott NC; Ryan EJ; O'Donovan N; Crown J; Duffy MJ
Endocr Relat Cancer; 2016 Apr; 23(4):323-34. PubMed ID: 26932782
[TBL] [Abstract][Full Text] [Related]
18. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
Buchanan G; Birrell SN; Peters AA; Bianco-Miotto T; Ramsay K; Cops EJ; Yang M; Harris JM; Simila HA; Moore NL; Bentel JM; Ricciardelli C; Horsfall DJ; Butler LM; Tilley WD
Cancer Res; 2005 Sep; 65(18):8487-96. PubMed ID: 16166329
[TBL] [Abstract][Full Text] [Related]
19. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
Traina TA; Miller K; Yardley DA; Eakle J; Schwartzberg LS; O'Shaughnessy J; Gradishar W; Schmid P; Winer E; Kelly C; Nanda R; Gucalp A; Awada A; Garcia-Estevez L; Trudeau ME; Steinberg J; Uppal H; Tudor IC; Peterson A; Cortes J
J Clin Oncol; 2018 Mar; 36(9):884-890. PubMed ID: 29373071
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
